Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) has formed a JV with Antisense Technologies of Australia to develop a drug discovered by ANB. The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma. TJAB will be responsible for marketing in China and Hong Kong, while ANB will retain those duties for the rest of the world. More details.... Stock Symbol: (ASX: ANB) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});